Dow Jones
33.949,01 -207,68 (-0,61%) Nasdaq
11.910,52 -203,27 (-1,68%) Nikkei 225
27.434,59 -171,87 (-0,62%) EUR/USD
1,0719 +0,0001 (+0,01%) BTC-EUR
21.451,41 -403,28 (-1,85%) CMC Crypto 200
529,63 -7,26 (-1,35%)
Aeterna Zentaris Inc. (AEZS)
Dopo ore:
| Chiusura precedente | 3,7900 |
| Aperto | 3,7873 |
| Denaro | 3,6500 x 1000 |
| Lettera | 3,9800 x 1000 |
| Min-Max giorno | 3,6900 - 3,7800 |
| Intervallo di 52 settimane | 2,8900 - 11,0000 |
| Volume | |
| Media Volume | 15.549 |
| Capitalizzazione | 18,247M |
| Beta (5 anni mensile) | 1,72 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,0790 |
| Prossima data utili | 27 mar 2023 - 31 mar 2023 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 28,00 |
- GlobeNewswire
Aeterna Zentaris Provides Business Update and Outlines Key Upcoming Milestones
Aeterna Zentaris focused on accelerating recruitment for ongoing DETECT trial and efforts to partner rights to Macrilen™ in the U.S. and CanadaCompany continues to build growing body of data across its development pipeline, advancing towards go/no-go decision milestones at each stage to establish prioritization and drive momentumStrategic decision to streamline development programs by discontinuing the Company’s early-stage vaccine programs provides Aeterna Zentaris with an expected extended cas
- GlobeNewswire
Aeterna Zentaris to Present at the Virtual Investor 2023 Companies to Watch Event
Live video webcast on Thursday, January 19th at 3:00 PM ET TORONTO, ONTARIO, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna Zentaris, will present at the Virtual Investor 2023 Companies to Watch Event on Thursday, January 1
- GlobeNewswire
Aeterna Zentaris Reports Third Quarter 2022 Financial Results
– Company ended the quarter with $53.8 million in cash – Driving continued progress across diversified pre-clinical and clinical development pipeline TORONTO, ONTARIO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (Nasdaq: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and operating results for the third quarter ended Sept
